Feb 05, 2019
InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
Jan 22, 2019
TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of-Concept Study of AC-203 for Treatment of Epidermolysis Bullosa
Jan 03, 2019
InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019
Nov 27, 2018
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
Nov 05, 2018
InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018
Oct 20, 2018
TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa
Oct 19, 2018
Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma
Oct 10, 2018
InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
Oct 08, 2018
Global Orphan and Rare Dermatology Drugs Market 2018-2024: Focus on Systemic Sclerosis, Alopecia, Epidermolysis Bullosa, Pemphigus Vulgaris, Vitiligo and Cutaneous Lupus Erythematosus
Sep 24, 2018
Study Reveals Protein Behind RDEB's Painful Symptoms and How Stem Cells Might Stop It
Aug 02, 2018
RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa
Aug 01, 2018
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
Jun 25, 2018
Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
May 23, 2018
BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa
May 16, 2018
Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
Apr 24, 2018
ARANZ Medical's pedigree in clinical trials makes Silhouette(R) the obvious choice for new research
Feb 26, 2018
TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa
Jan 15, 2018
Castle Creek Pharmaceuticals Announces Data Validating First Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research
Oct 27, 2017
BERG Honored with Partner in Progress Award from DEBRA of America at Annual Benefit for Rare Disease Epidermolysis Bullosa (EB)
Oct 27, 2017
Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America